REG - Abingdon Health PLC - Launch of OEM self-tests in Boots

Abingdon HealthAnnouncement

20/03/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240320:nRST4299Ha&default-theme=true

RNS Number : 4299H  Abingdon Health PLC  20 March 2024

 

Abingdon Health plc

("Abingdon Health" or "the Company")

 

Launch of OEM self-tests in Boots

Boots to sell its first own brand self-tests in stores and online across the
UK provided by Abingdon Health and Crest Medical partnership.

 

York, U.K. 20(th) March 2024: Abingdon Health plc (AIM: ABDX), a leading
international lateral flow Contract Development and Manufacturing Organisation
(CDMO), announces the launch of Boots' own-brand, rapid self-tests across the
UK and online in partnership with Crest Medical.

 

In a significant step forward in strengthening its position in the consumer
lateral flow self-test market, Abingdon Health is launching the first two
products - Iron and Vitamin D deficiency self-tests - in this Boots own-brand
range, with the self-tests being made available in stores and online at
Boots.com from Spring 2024. These products will sit within the Boots family of
branded products which will increase consumer confidence in the continued
adoption of at-home testing.

 

As a CRO/CDMO of lateral flow tests, Abingdon Health is uniquely positioned to
offer Original Equipment Manufacturer (OEM) self-tests under its own brand
families to partners throughout the UK and Europe as a value-add Private Label
Supplier (PLS). The global lateral flow assay market size is expected to reach
USD $23 billion by 2027(1) and with consumer adoption of self-tests on the
rise (US $7.89 billion in 2023)(2), this has coincided with retailers looking
to offer these products under their own brands to improve their consumer
offering.

 

Chris Yates, CEO of Abingdon Health plc, commented: "We are delighted to
announce the launch of the Boots own-brand Iron and Vitamin D deficiency
self-tests in conjunction with our partner Crest Medical. As lateral flow
experts we're proud to offer a comprehensive private label service to
retailers covering a broad range of self-tests, including innovative exclusive
products from Abingdon's CDMO customers. We take immense pride in the quality
of our service and ensure a seamless supply of innovative lateral flow
self-tests to ensure our partners requirements are met."

 

Matthew Courtney, CEO of Crest Medical Ltd, commented: "Diagnostic tests are
another great addition to the Crest Medical portfolio as we look to expand
further and deepen our partnership with Boots. Abingdon Health are at the
forefront of this expansion and we are thrilled to be partnering with a
company who are leaders in lateral flow diagnostics."

 

 

Sources:

1.     1. Lateral Flow Assays Market worth $22.6 billion |
MarketsandMarkets | ABNewswire
(https://www.abnewswire.com/pressreleases/lateral-flow-assays-market-worth-226-billion-marketsandmarkets_645449.html)

2.     Self-testing Market Share, Growth, Demand, Forecast to 2033
(futuremarketinsights.com)
(https://www.futuremarketinsights.com/reports/self-testing-market)

 

Enquiries

 

 Abingdon Health plc                                           www.abingdonhealth.com/investors/ (http://www.abingdonhealth.com/investors/)
 Chris Yates, Chief Executive Officer
 Chris Hand, Non-Executive Chairman

 Singer Capital Markets (Sole Broker and Nominated Adviser)    Tel: +44 (0)20 7496 3000
 Peter Steel, Alex Bond, Jalini Kalaravy (Corporate Finance)
 Tom Salvesen (Corporate Broking)

 

About Abingdon Health plc

 

Abingdon Health is a leading lateral flow contract development and
manufacturing organisation ("CDMO") offering its services to an international
customer base across industry sectors that include clinical, animal health,
plant health, and environmental testing. Abingdon Health has the internal
capabilities to take projects from initial concept through to routine and
large-scale manufacturing; from "idea to commercial success."

 

The Company's CDMO division offers product development, regulatory support,
technology transfer and manufacturing services for customers looking to
develop new assays or transfer existing laboratory-based assays to a lateral
flow format. Abingdon Health aims to support the increase in need for rapid
results across many industries and locations and produces lateral flow tests
in areas such as infectious disease, clinical testing including companion
diagnostics, animal health and environmental testing. Faster access to results
allows for rapid decision making, targeted intervention and can support better
outcomes.

 

Abingdon Health's Abingdon Simply Test range of self-tests is an ecommerce
platform that offers a range of self-tests to empowers consumers to manage
their own health and wellbeing. The Abingdon Simply Test
(http://www.abingdonsimplytest.com) ecommerce site offers consumers a range of
information to support them in making informed decisions on the tests
available. In addition, the site provides Abingdon's contract services
customers with a potential route to market for self-tests. The Abingdon Simply
Test range is also sold through international distributors and through other
channels in the UK and Ireland such as pharmacy chains.

 

Founded in 2008, Abingdon Health is headquartered in York, England.

 

For more information visit: www.abingdonhealth.com
(http://www.abingdonhealth.com/)

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCQKCBQKBKDBND